Optogenetic Opsins for Selective Neural Stimulation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Electrode-based brain stimulation techniques face challenges due to the distributed nature of neurons, making it difficult to selectively stimulate specific neuron types, and they often suffer from mechanical instability and encapsulation issues, leading to unintended stimulation of additional cells.

Innovation Solution

The use of blue-light sensing opsins, such as GtR3 and DChR, which are engineered to respond to light by producing inhibitory or excitatory currents, allowing for precise control of neural activity by introducing these proteins into cells and applying specific light spectra.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If electrode-based stimulation is used to stimulate neurons, then neural activity can be activated, but selective stimulation of specific neuron types is difficult due to the distributed nature of neurons

Engineering Contradiction:
Improveselectivity of neuron stimulationVSAvoidcomplexity of electrode placement and control
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The invention divides the stimulation approach into two separate components: (1) genetic targeting that segments specific neuron types through selective expression of light-sensitive proteins, and (2) optical stimulation that provides precise spatial control. This segmentation allows independent optimization of cell-type selectivity and stimulation precision without the trade-off present in electrode-based methods.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention introduces light-sensitive proteins (opsins, channelrhodopsins) as intermediary molecules that convert optical energy into electrical signals in neurons. These intermediaries enable indirect stimulation through a molecular mediator, allowing precise control of neural activity with light while avoiding the physical constraints and lack of selectivity inherent in direct electrode-based stimulation.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If electrode placement is used to target specific neurons, then stimulation can be delivered, but mechanical stability is inadequate leading to lead migration

Engineering Contradiction:
Improvestability of electrode placementVSAvoidprecision of targeted stimulation
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The invention replaces the mechanical electrode-brain interface with a biochemical-optical system. Instead of relying on mechanically stable electrode placement, the approach uses genetically encoded light-sensitive proteins that are selectively expressed in target neurons. This substitution eliminates mechanical instability and lead migration issues while maintaining or improving stimulation precision through optical control.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention changes the fundamental parameter of stimulation delivery from electrical (electrodes) to optical (light). This parameter change enables precise spatial and temporal control of neural activation without the mechanical stability constraints that limit electrode-based methods. The optical parameter allows for non-invasive, stable, and highly selective neuronal manipulation.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If electrode voltage or frequency is increased to compensate for encapsulation, then electrical power delivery is improved, but unintended stimulation of additional cells increases

Engineering Contradiction:
Improveelectrical power deliveryVSAvoidunintended stimulation of cells
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention applies local quality by using genetically targeted expression of light-sensitive proteins in specific neuron types or brain regions. This creates locally differentiated sensitivity to light stimulation, allowing precise control of which cells are activated. The effect is confined to cells expressing the transgene, eliminating the spread of stimulation to unintended cells that occurs with increased electrode power.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The light-sensitive proteins serve as intermediaries that convert optical energy into localized electrical signals only in expressing cells. This intermediary mechanism provides inherent spatial confinement of the stimulation effect, as only cells with the expressed protein can respond to the light. This eliminates the need to increase voltage or frequency to overcome encapsulation, as the optical approach naturally provides sufficient power delivery without affecting non-target cells.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables targeted and controlled stimulation of neural activity, reducing unintended stimulation and improving mechanical stability, allowing for precise modulation of neural activity and potential therapeutic applications.

Implementation Method 1

blue-light sensing opsins, such as GtR3 and DChR, which are engineered to respond to light by producing inhibitory or excitatory currents

Methodology Applied
Scientific EffectPhotoelectric Effect: Photoelectric Effect

Data Source

PatentUS9604073B2Light-sensitive ion-passing molecules
Publication Date: 2017.03.28 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
  • US9604073B2 patent drawing
  • US9604073B2 patent drawing
  • US9604073B2 patent drawing

AI summary

The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.